Personalis (PSNL) Stock Price, News & Analysis

Company Overview

Personalis, Inc. (NASDAQ:PSNL) is a leading provider of advanced genomic sequencing and analytics solutions focused on precision immuno-oncology. Founded in 2011 and headquartered in Menlo Park, California, the company operates CAP-accredited and CLIA-certified laboratories in the United States and China. Personalis leverages next-generation sequencing (NGS) technologies to generate high-resolution genomic data that inform cancer immunotherapy research, biomarker discovery, and the development of personalized cancer vaccines.

The company’s core offerings include the ImmunoID NeXT™ platform, which integrates whole-exome and transcriptome sequencing with proprietary immunogenomic analytics to characterize the tumor and its microenvironment. Through products such as the neoantigen characterization engine (NeXT Engine™) and the ACE™ Pan-Cancer Panel, Personalis provides comprehensive profiling of tumor mutational burden, HLA typing, neoantigen prediction and immune repertoire sequencing. These services support pharmaceutical and biotechnology customers in clinical trial design, patient stratification and biomarker validation for novel immunotherapies.

Personalis serves a global client base across North America, Asia and Europe, partnering with leading academic institutions, contract research organizations and major pharmaceutical companies to advance precision medicine initiatives. The company’s leadership team is led by Chair and CEO Dr. Jia Li, a genomic sequencing pioneer with experience at the Broad Institute and Illumina, and COO Dr. David Daly, former head of oncology biomarker development at Thermo Fisher Scientific. Together, they guide Personalis’s strategic growth in immuno-oncology genomics, supporting the industry’s shift toward data-driven, individualized cancer treatment approaches.

Key Stats

• Today's Range: $6.35 to $6.86
• 50-Day Range: $4.00 to $7.56
• 52-Week Range: $1.61 to $7.79
• Volume: 1.23 million shs
• Average Volume: 1.16 million shs
• Market Capitalization: $562.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.67
• Consensus Rating: Buy

Personalis Stock Analysis - MarketRank™

Personalis scored higher than 70% of companies evaluated by MarketBeat, and ranked 304th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Personalis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Personalis has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Personalis are expected to grow in the coming year, from ($1.40) to ($0.99) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Personalis is -4.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Personalis is -4.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Personalis has a P/B Ratio of 2.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.23% of the float of Personalis has been sold short.

Short Interest Ratio / Days to Cover

Personalis has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Personalis has recently increased by 59.07%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Personalis does not currently pay a dividend.

Dividend Growth

Personalis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.66

Percentage of Shares Shorted

7.23% of the float of Personalis has been sold short.

Short Interest Ratio / Days to Cover

Personalis has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Personalis has recently increased by 59.07%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.38

News Sentiment

Personalis has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Personalis this week, compared to 3 articles on an average week.

Search Interest

8 people have searched for PSNL on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Personalis to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Personalis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,186.00 in company stock.

Percentage Held by Insiders

Only 3.80% of the stock of Personalis is held by insiders.

Percentage Held by Institutions

61.91% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PSNL Stock Analysis - Frequently Asked Questions

How have PSNL shares performed this year?

Personalis' stock was trading at $5.78 at the beginning of 2025. Since then, PSNL stock has increased by 10.2% and is now trading at $6.37.

How were Personalis' earnings last quarter?

Personalis, Inc. (NASDAQ:PSNL) released its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.05. The firm had revenue of $20.61 million for the quarter, compared to analysts' expectations of $17.41 million. Personalis had a negative trailing twelve-month return on equity of 48.78% and a negative net margin of 98.10%.
Read the conference call transcript.

When did Personalis IPO?

Personalis (PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.

How do I buy shares of Personalis?

Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Personalis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Personalis investors own include Digital Turbine (APPS), CrowdStrike (CRWD), Okta (OKTA), Unity Software (U) and Vuzix (VUZI).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - GENERIC DRG
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:PSNL
• CIK: 1527753
• Web: www.personalis.com
• Phone: (650) 752-1300
• Fax: N/A
• Employees: 400
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Personalis: $7.67
• High Price Target: $9.00
• Low Price Target: $6.00
• Potential Upside/Downside: +20.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$81.28 million
• Net Margins: -98.10%
• Pretax Margin: -98.08%
• Return on Equity: -48.78%
• Return on Assets: -34.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.91
• Quick Ratio: 6.74

Sales & Book Value

• Annual Sales: $84.61 million
• Price / Sales: 6.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.87 per share
• Price / Book: 2.22

Miscellaneous

• Outstanding Shares: 88,320,000
• Free Float: 84,969,000
• Market Cap: $562.60 million
• Optionable: Optionable
• Beta: 1.95